Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Core Viewpoint - Dynavax Technologies Corporation is set to report its second quarter 2025 financial results on August 7, 2025, after U.S. financial markets close, indicating ongoing operations and potential growth in the biopharmaceutical sector [1]. Company Overview - Dynavax is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines to combat infectious diseases [3]. - The company has two commercial products: HEPLISAV-B® vaccine, approved in the U.S., EU, and UK for preventing hepatitis B virus infections in adults aged 18 and older, and CpG 1018® adjuvant, utilized in HEPLISAV-B and various adjuvanted COVID-19 vaccines [3]. Upcoming Events - A conference call and live audio webcast will be held on August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT, allowing investors to engage with the company's financial updates [1][2]. - Participants are encouraged to register for the call and join approximately 10 minutes early to ensure a smooth experience [2]. Investor Relations - Contact information for investor inquiries is provided, including Paul Cox and Nicole Arndt, with respective email addresses and phone numbers for further communication [4].